Hall 2011.
Methods | BUPROPION Randomized controlled trial Setting: Clinic, USA Recruitment: community volunteers |
|
Participants | 406 smokers of ≥ 10 cpd 39% F, av age 41, av cpd 19, mean FTND 4.9 |
|
Interventions | Relapse prevention study. All arms received same cessation intervention (5 sessions group counselling, 10wks NRT and 12wks bupropion at 150 mg/d for first 3 days and 300 mg/d for remainder). After cessation treatment ended: 1. Bupropion for 40wks (300mg/d) 2. As per 1, but placebo 3. As per 1, plus 11 sessions of individual CBT over 40 wks 4. As per 3, but placebo 5. No further treatment |
|
Outcomes | 7d PP at 2y CO ≤ 10 ppm and urinary cotinine ≤ 60 ng/ml |
|
Notes | New for 2013 update. Study report does not present absolute values for N abstinent, only adjusted ORs. N quit extrapolated from graph. Group 5 does not contribute to any analyses. Funding: National Institute on Drug Abuse |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | “Randomly assigned,” methods not specified |
Allocation concealment (selection bias) | Unclear risk | Not specified |
Blinding (performance bias and detection bias) All outcomes | Unclear risk | Participants blinded successfully but blinding of staff not reported |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | 83% followed up at 2y, similar rates across groups |